The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition

• Status: Terminated
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study will determine in obese subjects the direct effects of the weight loss drug rimonabant (ie independent of weight loss) on energy expenditure, fat metabolism and and body fat distribution. We hypothesise that rimonabant will increase energy expenditure. The fuel for the increased energy expenditure will come from fat. As a result of burning more fat there will be a decrease in fat in blood and an improvement in the body's response to insulin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Surrey
• Collaborators: European Foundation for the Study of Diabetes; Royal Surrey County Hospital; Royal Surrey County Hospital NHS Foundation Trust
• Treatments: Rimonabant

Criteria

Inclusion Criteria:

• Healthy Caucasian postmenopausal women

• BMI 30-38

Exclusion Criteria:

• Not currently weight-stable

• Diagnosed with diabetes

• Cardiovascular disease

• Endocrine disease

• Hepatic and renal disorders

• Neurological/psychological illness/history of depression

• Previous surgical procedures for weight loss

• Medications known to alter body weight or appetite

• β-blockers, fibrates and metformin

• Severe under-reporting of food intake based on a 4 day food diary